|Table of Contents|

Advances in research on adrenergic receptors in cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 23
Page:
4522-4530
Research Field:
Publishing date:

Info

Title:
Advances in research on adrenergic receptors in cancer
Author(s):
SHEN Shixiong1; 2; 3; 4; DING Mengmeng1; 3; 4; HAN Jiaxuan1; 3; 4; MENG Xinyu1; 3; 4; LIU Yuan1; 3; 4; CHU Ming1; 3; 4; LI Min2; WANG Yuedan1; 3; 4
1.Department of Immunology,School of Basic Medical Sciences,Peking University,Beijing 100191,China;2.Department of Anesthesiology,Peking University Third Hospital,Beijing 100191,China;3.Key Laboratory of Medical Immunology,National Health Commission,Beijing 100191,China;4.Comprehensive Laboratory of Pathogens and Immunology,Biomedical Experimental Teaching Center,Peking University,Beijing 100191,China.
Keywords:
adrenergic receptors; immune regulation; immunotherapy; signal transduction; cancer therapy
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2024.23.016
Abstract:
Adrenergic receptors are prominently expressed on immune cells,and recent studies have increasingly highlighted their critical role in immunoregulation.In oncology,numerous studies have identified adrenergic receptors as potential novel targets for cancer therapy.Specifically,α-adrenergic receptors influence cancer growth and metastasis by modulating immune cell migration and cytokine secretion,while β-adrenergic receptors play a significant role in cancer immune evasion by mediating immunosuppressive signaling pathways within the tumor microenvironment.Research on the role of adrenergic receptors in cancer not only deepens our understanding of cancer immunoregulation mechanisms but also provides a theoretical basis for developing novel cancer immunotherapy strategies.This paper reviews recent advances in the study of adrenergic receptors in cancer,discussing their key roles and potential applications in cancer immune regulation.It also examines the three-dimensional structure of adrenergic receptor proteins,summarizes the regulators of adrenergic receptors and their primary effects,and compiles the impact of certain adrenergic receptor agonists and antagonists on cancer treatment.

References:

［1］HAN B,ZHENG R,ZENG H,et al.Cancer incidence and mortality in China,2022［J］.Journal of the National Cancer Center,2024,4(1):47-53.
［2］DOCHERTY JR.The pharmacology of α1-adrenoceptor subtypes［J］.European Journal of Pharmacology,2019,855:305-320.
［3］KAMIAR A,YOUSEFI K,DUNKLEY JC,et al.β2-Adrenergic receptor agonism as a therapeutic strategy for kidney disease［J］.American Journal of Physiology-Regulatory,Integrative and Comparative Physiology,2021,320(5):R575-R587.
［4］PADRO CJ,SANDERS VM.Neuroendocrine regulation of inflammation［J］.Seminars in Immunology,2014,26(5):357-368.
［5］LI Z,LIN Y,SONG H,et al.First small-molecule PROTACs for G protein-coupled receptors:inducing α1A-adrenergic receptor degradation［J］.Acta Pharmaceutica Sinica.B,2020,10(9):1669-1679.
［6］EFESOY O,SAYLAM B,TEK M,et al.Is there any priority between the alpha blockers on voiding functions after transrectal ultrasound guided prostate biopsy［J］.Turkish Journal of Urology,2021,47(2):137-143.
［7］SUN X,YANG S,SONG W.Prazosin inhibits the proliferation and survival of acute myeloid leukaemia cells through down-regulating TNS1［J］.Biomedicine & Pharmacotherapy,2020,124:109731.
［8］SPENCER BH,MCDERMOTT CM,CHESS-WILLIAMS R,et al.Prazosin but not tamsulosin sensitises PC-3 and LNCaP prostate cancer cells to docetaxel［J］.Pharmacology,2018,102(1-2):10-18.
［9］AN M,MA WH,JIA HW,et al.Prazosin inhibits the growth and mobility of osteosarcoma cells［J］.Translational Cancer Research,AME Publishing Company,2019,8(5):1997-2004.
［10］BROSO F,GATTO P,SIDAROVICH V,et al.Alpha-1 adrenergic antagonists sensitize neuroblastoma to therapeutic differentiation［J］.Cancer Research,2023,83(16):2733-2749.
［11］KING L,CHRISTIE D,DARE W,et al.Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment:From bench to bedside［J］.European Journal of Pharmacology,2021,893:173831.
［12］FLORENT R,POULAIN L,N'DIAYE M.Drug repositioning of the α1-adrenergic receptor antagonist naftopidil:A potential new anti-cancer drug［J］.International Journal of Molecular Sciences,2020,21(15):5339.
［13］HUAN HB,WEN XD,CHEN XJ,et al.Sympathetic nervous system promotes hepatocarcinogenesis by modulating inflammation through activation of alpha1-adrenergic receptors of Kupffer cells［J］.Brain,Behavior,and Immunity,2017,59:118-134.
［14］LIU D,XU X,DAI Y,et al.Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment［J］.Journal for ImmunoTherapy of Cancer,2021,9(1):e001466.
［15］YUKI K.The immunomodulatory mechanism of dexmedetomidine［J］.International Immunopharmacology,2021,97:107709.
［16］PEREZ PC,RIVERO EM,GARGIULO L,et al.Adrenergic receptors in breast cancer［J］.Progress in Molecular Biology and Translational Science,2022,193(1):37-63.
［17］WANG C,DATOO T,ZHAO H,et al.Midazolam and dexmedetomidine affect neuroglioma and lung carcinoma cell biology in vitro and in vivo［J］.Anesthesiology,2018,129(5):1000-1014.
［18］ZHU J,NAULAERTS S,BOUDHAN L,et al.Tumour immune rejection triggered by activation of α2-adrenergic receptors［J］.Nature,2023,618(7965):607-615.
［19］WANG K,WU M,XU J,et al.Effects of dexmedetomidine on perioperative stress,inflammation,and immune function:systematic review and meta-analysis［J］.British Journal of Anaesthesia,2019,123(6):777-794.
［20］JUN JH,SHIM JK,OH JE,et al.Effects of dexmedetomidine on A549 non-small cell lung cancer growth in a clinically relevant surgical xenograft model［J］.Scientific Reports,2023,13(1):12471.
［21］CARNET LE PROVOST K,KEPP O,KROEMER G,et al.Trial watch:dexmedetomidine in cancer therapy［J］.Oncoimmunology,2024,13(1):2327143.
［22］XING XW,SUN YF,ZHAO J,et al.Tizanidine hydrochloride exhibits a cytotoxic effect on osteosarcoma cells through the PI3K/AKT signaling pathway［J］.The Journal of International Medical Research,2019,47(8):3792-3802.
［23］MACCARI S,BUONCERVELLO M,ASCIONE B,et al.α-Adrenoceptor stimulation attenuates melanoma growth in mice［J］.British Journal of Pharmacology,2022,179(7):1371-1383.
［24］PADRO CJ,SANDERS VM.Neuroendocrine regulation of inflammation［J］.Seminars in Immunology,2014,26(5):357-368.
［25］HARA MR,KOVACS JJ,WHALEN EJ,et al.A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1［J］.Nature,2011,477(7364):349-353.
［26］AMMONS DT,MACDONALD CR,CHOW L,et al.Chronic adrenergic stress and generation of myeloid-derived suppressor cells:Implications for cancer immunotherapy in dogs［J］.Veterinary and Comparative Oncology,2023,21(2):159-165.
［27］GLOBIG AM,ZHAO S,ROGINSKY J,et al.The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion［J］.Nature,2023,622(7982):383-392.
［28］HULSURKAR M,LI Z,ZHANG Y,et al.Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1［J］.Oncogene,2017,36(11):1525-1536.
［29］COELHO M,SOARESSILVA C,BRANDAO D,et al.β-Adrenergic modulation of cancer cell proliferation:available evidence and clinical perspectives［J］.Journal of Cancer Research and Clinical Oncology,2017,143(2):275-291.
［30］ZHANG D,MA Q,WANG Z,et al.β2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathway［J］.Molecular Cancer,2011,10:146.
［31］ZHANG X,ZHANG Y,HE Z,et al.Chronic stress promotes gastric cancer progression and metastasis:an essential role for ADRB2［J］.Cell Death & Disease,2019,10(11):788.
［32］COELHO M,MOZ M,CORREIA G,et al.Antiproliferative effects of β-blockers on human colorectal cancer cells［J］.Oncology Reports,2015,33(5):2513-2520.
［33］ZABOROWSKASZMIT M,SZMIT S,OLSZYNASEREMENTA M,et al.Beta blockers with statins may decrease all-cause mortality in patients with cardiovascular diseases and locally advanced unresectable non-small-cell lung cancer after chemoradiotherapy［J］.Cancers,2023,15(4):1277.
［34］OH MS,GUZNER A,WAINWRIGHT DA,et al.The impact of Beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors［J］.Clinical Lung Cancer,2021,22(1):e57-e62.
［35］FAROOQ MA,AJMAL I,HUI X,et al.β2-adrenergic receptor mediated inhibition of T cell function and its implications for CAR-T cell therapy［J］.International Journal of Molecular Sciences,2023,24(16):12837.
［36］YAN X,LIU P,LI D,et al.Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors［J］.International Immunopharmacology,2022,113:109383.
［37］SHI DD,GUO JA,HOFFMAN HI,et al.Therapeutic avenues for cancer neuroscience:translational frontiers and clinical opportunities［J］.The Lancet Oncology,2022,23(2):e62-e74.
［38］WU FQ,FANG T,YU LX,et al.ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α［J］.Journal of Hepatology,2016,65(2):314-324.
［39］CHANG CH,LEE CH,KO JC,et al.Effect of β-blocker in treatment-naive patients with advanced lung adenocarcinoma receiving first-generation EGFR-TKI［J］.Frontiers in Oncology,2020,10:583529.

Memo

Memo:
National Natural Science Foundation of China（No.SQ2021YFE020462）;国家重点研发项目（编号：SQ2021YFE020462）
Last Update: 2024-11-01